Zacks Research Cuts Earnings Estimates for Tenet Healthcare

Tenet Healthcare Co. (NYSE:THC) – Stock analysts at Zacks Research reduced their Q3 2025 EPS estimates for Tenet Healthcare in a research report issued on Tuesday, May 13th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $2.25 for the quarter, down from their previous forecast of $2.75. The consensus estimate for Tenet Healthcare’s current full-year earnings is $12.24 per share. Zacks Research also issued estimates for Tenet Healthcare’s Q4 2025 earnings at $3.09 EPS, Q1 2026 earnings at $3.48 EPS and Q1 2027 earnings at $3.55 EPS.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $1.25. The business had revenue of $5.22 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Tenet Healthcare had a net margin of 15.48% and a return on equity of 21.88%. The business’s revenue was down 2.5% on a year-over-year basis. During the same period last year, the firm posted $3.22 earnings per share.

Several other research firms have also commented on THC. UBS Group increased their target price on shares of Tenet Healthcare from $217.00 to $230.00 and gave the company a “buy” rating in a research note on Wednesday, April 30th. Robert W. Baird reissued a “neutral” rating and set a $137.00 target price (down from $153.00) on shares of Tenet Healthcare in a research note on Tuesday, April 15th. Royal Bank of Canada increased their target price on shares of Tenet Healthcare from $183.00 to $189.00 and gave the company an “outperform” rating in a research note on Wednesday, April 30th. Morgan Stanley increased their target price on shares of Tenet Healthcare from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Monday, May 5th. Finally, StockNews.com raised shares of Tenet Healthcare from a “hold” rating to a “buy” rating in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $174.94.

Tenet Healthcare Trading Up 0.9%

Tenet Healthcare stock opened at $165.55 on Friday. The firm has a 50 day simple moving average of $132.78 and a 200-day simple moving average of $136.29. The company has a debt-to-equity ratio of 2.25, a current ratio of 1.78 and a quick ratio of 1.70. The stock has a market capitalization of $15.38 billion, a PE ratio of 5.14, a price-to-earnings-growth ratio of 1.02 and a beta of 1.63. Tenet Healthcare has a 12-month low of $109.82 and a 12-month high of $171.20.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Tenet Healthcare by 6.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,596,544 shares of the company’s stock worth $1,021,736,000 after purchasing an additional 463,552 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Tenet Healthcare by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,116,121 shares of the company’s stock worth $268,591,000 after purchasing an additional 71,454 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Tenet Healthcare by 348.4% during the 1st quarter. Ameriprise Financial Inc. now owns 1,962,314 shares of the company’s stock worth $263,905,000 after purchasing an additional 1,524,642 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Tenet Healthcare by 12.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,675,199 shares of the company’s stock worth $225,297,000 after purchasing an additional 181,667 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Tenet Healthcare during the 1st quarter worth $218,549,000. Institutional investors and hedge funds own 95.44% of the company’s stock.

Insider Buying and Selling at Tenet Healthcare

In other Tenet Healthcare news, EVP Paola M. Arbour sold 6,461 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $160.20, for a total value of $1,035,052.20. Following the transaction, the executive vice president now owns 27,848 shares in the company, valued at approximately $4,461,249.60. This represents a 18.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Robert Kerrey sold 5,001 shares of the company’s stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $148.50, for a total transaction of $742,648.50. Following the completion of the transaction, the director now owns 22,377 shares in the company, valued at approximately $3,322,984.50. This represents a 18.27% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,987 shares of company stock worth $2,972,421. 0.81% of the stock is currently owned by company insiders.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.